Evofem Biosciences, Inc. (EVFM) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Assets
Current assets:
Cash and cash equivalents	2.8	7.7	48.9	15.6	1.3	1.2	11.5	37.7
Restricted cash	1.2	5.1	22.6	0.3	0.4	0.5	0.2
Trade accounts receivable, net	1.1	6.4	1.1
Inventories	5.4	7.7	7.2
Prepaid and other current assets	2.2	3.2	18.1	2.3	0.7	0.7	1.0	2.0
Total current assets	12.7	30.1	97.7	26.4	2.5	2.4	12.5	39.7
Property and equipment, net	3.9	5.8	4.3	0.4	0.6	0.8	0.1	0.2
Operating lease right-of-use assets	4.4	5.4	6.9	0.2
Other noncurrent assets	4.1	1.2	1.0	1.3	0.9	0.8
Total assets	25.2	42.5	110.0	28.3	4.0	4.0	12.8	40.1

Liabilities, convertible and redeemable preferred stock and stockholders’ deficit
Current liabilities:
Accounts payable	15.0	10.3	10.6	6.0	8.9	9.0	0.5	4.0
Accrued expenses	4.1	8.4	8.1	5.3	11.5	12.1	0.4	0.9
Accrued compensation	2.2	4.7	6.5	3.7	2.9	2.4
Derivative liabilities	1.7	0.2				79.9
Other current liabilities	2.9	2.9	1.0
Total current liabilities	93.8	137.7	77.3	12.7	27.3	103.3	0.9	9.1
Total liabilities	97.0	142.1	108.6	12.7	27.4	103.6

Commitments and contingencies (Note 7)
Convertible and redeemable preferred stock, $0.0001 par value
Series B-1, B-2, and C convertible preferred stock, 5,000, 5,000, and 1,700 shares authorized; no shares issued and outstanding at June 30, 2023 and December 31, 2022
Stockholders’ deficit:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding at June 30, 2023 and December 31, 2022
Common Stock, $0.0001 par value; 500,000,000 shares authorized; 2,524,239 and 984,786 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively
Additional paid-in capital	817.4	751.3	656.8	528.8	409.8	17.7	137.8	136.6
Accumulated other comprehensive income	49.5	5.1
Accumulated deficit	-938.7	-860.7	-655.5	-513.2	-433.1	-307.3	-125.9	-112.8
Total stockholders’ deficit	-71.8	-104.3	1.3	15.6	-23.4	-289.5	11.9	23.8
Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit	25.2	42.5	110.0	28.3	4.0	4.0	12.8	40.1